Abstract: The present invention provides an antibody to a fibrosis-related molecule and medical application thereof. The antibody of the present invention is an antibody that binds to CHL1 protein and an antibody that neutralizes the binding of the CHL1 protein to a fibroblast.

Abstract: The present embodiments provide compositions and methods related to novel recombinant protein immunogens, comprising specific portions of alpha helical domains (aHD) and proline rich regions (PRD) of pneumococcal surface protein A (PspA), which portions are linked to provide aHD-PRD constructs. The aHD and PRD proteins constituting the aHD-PRD constructs are selected to maximize cross-reactivity and provide protection against a broad spectrum of pneumococcal serotypes. Immunogenic compositions, including vaccines, comprising at least one aHD PRD construct may also include a non-linked aHD portion. Also provided are recombinant nucleic acid molecules that encode aHD-PRD constructs, vectors and recombinant host cells containing such molecules, aHD-PRD expression products, use of such nucleic acid molecules to express aHD-PRD constructs by recombinant techniques, and use of the expression products to elicit an immune or protective response against pneumococcal disease in a suitable host.

Abstract: It is to provide intestinal symbiotic bacteria having an action of increasing an IgA content in milk. An agent containing one or more bacterial strains selected from: a bacterial strain of the genus Bacteroides which has a 16S rRNA gene having at least 90% identity to the nucleotide sequence represented by SEQ ID NO: 1, and has an action of increasing an IgA antibody content in milk; and a bacterial strain of the genus Prevotella which has a 16S rRNA gene having at least 90% identity to the nucleotide sequence represented by SEQ ID NO: 2, and has an action of increasing an IgA antibody content in milk is used as an agent for increasing an IgA antibody content in milk.

Abstract: The present invention provides a nanogel nasal vaccine that induces cell-mediated immunity. The present invention relates to a vaccine preparation comprising a complex of a nanogel, a vaccine antigen, and an adjuvant, wherein the vaccine preparation can efficiently induce the cell-mediated immunity, and can also induce a systemic and mucosal immune response.

Abstract: An antibody is provided that inhibits infection of cells with a norovirus. The antibody is a nanoantibody comprising a polypeptide described in (a), (b), or (c), and inhibiting infection of intestinal cells with HuNoV GII.4: (a) a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, or SEQ ID NO: 13; (b) a polypeptide consisting of an amino acid sequence comprising a substitution, deletion, insertion and/or addition of one or several amino acids with respect to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, or SEQ ID NO: 13; and (c) a polypeptide consisting of an amino acid sequence having a sequence identity of 80% or more to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, or SEQ ID NO: 13.

Abstract: The present invention provides D39-derived mutant PspA that does not undergo deamination and maintains stability as a molecule even around neutral pH range. Specifically, the present invention relates to a protein of the following (a) or (b): (a) a protein comprising the amino acid sequence as set forth in SEQ ID NO: 2 and having pneumococcal vaccine antigenic activity, and a protein substantially identical to the protein; or (b) a protein being a part of the amino acid sequence as set forth in SEQ ID NO: 2, wherein aspartic acid at position 254 is comprised in the part, and having pneumococcal vaccine antigenic activity, and a protein substantially identical to the protein.

Abstract: A magnetic field detection device includes a magnetic field detection element, a modulation coil, and a demodulator. The magnetic field detection element has a sensitivity axis in a first direction. The modulation coil is configured to apply, to the magnetic field detection element, an alternating current magnetic field having a first frequency and a component in a second direction, the second direction being orthogonal to the first direction. The demodulator is configured to demodulate an output signal having the first frequency and outputted from the magnetic field detection element, and detect, on a basis of an amplitude of the output signal, an intensity of a measurement magnetic field to be received by the magnetic field detection element.

Abstract: A magnetic field detection device includes a magnetism detection element, a modulator, and a demodulator. The magnetism detection element has a sensitivity axis along a first direction. The modulator is configured to impart a spin torque to the magnetism detection element. The spin torque has a rotational force and oscillates at a first frequency. The rotational force is exerted on a plane including the first direction and a second direction orthogonal to the first direction. The demodulator is configured to demodulate an output signal received from the magnetism detection element and to detect an intensity of a measurement target magnetic field exerted on the magnetism detection element on the basis of an amplitude of the output signal. The output signal has the first frequency.

Abstract: The present invention provides an antibody to a fibrosis-related molecule and medical application thereof. The antibody of the present invention is an antibody that binds to CHL1 protein and an antibody that neutralizes the binding of the CHL1 protein to a fibroblast.

Abstract: The present invention provides a nanogel nasal vaccine that induces cell-mediated immunity. Specifically, the present invention relates to a vaccine preparation comprising a complex of a nanogel, a vaccine antigen, and an adjuvant, wherein the vaccine preparation can efficiently induce the cell-mediated immunity, and can also induce a systemic and mucosal immune response.

Abstract: The present invention provides an antibody to a fibrosis-related molecule and medical application thereof. The antibody of the present invention is an antibody that binds to CHL1 protein and an antibody that neutralizes the binding of the CHL1 protein to a fibroblast.

Abstract: An antibody is provided that inhibits infection of cells with a norovirus. The antibody is a nanoantibody comprising a polypeptide described in (a), (b), or (c), and inhibiting infection of intestinal cells with HuNoV GII.4: (a) a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, or SEQ ID NO: 13; (b) a polypeptide consisting of an amino acid sequence comprising a substitution, deletion, insertion and/or addition of one or several amino acids with respect to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, or SEQ ID NO: 13; and (c) a polypeptide consisting of an amino acid sequence having a sequence identity of 80% or more to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, or SEQ ID NO: 13.

Abstract: A magnetic field detection device includes a magnetism detection element, a modulator, and a demodulator. The magnetism detection element has a sensitivity axis along a first direction. The modulator is configured to impart a spin torque to the magnetism detection element. The spin torque has a rotational force and oscillates at a first frequency. The rotational force is exerted on a plane including the first direction and a second direction orthogonal to the first direction. The demodulator is configured to demodulate an output signal received from the magnetism detection element and to detect an intensity of a measurement target magnetic field exerted on the magnetism detection element on the basis of an amplitude of the output signal. The output signal has the first frequency.

Abstract: A magnetic field detection device includes a magnetic field detection element, a modulation coil, and a demodulator. The magnetic field detection element has a sensitivity axis in a first direction. The modulation coil is configured to apply, to the magnetic field detection element, an alternating current magnetic field having a first frequency and a component in a second direction, the second direction being orthogonal to the first direction. The demodulator is configured to demodulate an output signal having the first frequency and outputted from the magnetic field detection element, and detect, on a basis of an amplitude of the output signal, an intensity of a measurement magnetic field to be received by the magnetic field detection element.

Abstract: The present invention provides an antibody to a fibrosis-related molecule and medical application thereof. The antibody of the present invention is an antibody that binds to CHL1 protein and an antibody that neutralizes the binding of the CHL1 protein to a fibroblast.

Abstract: The present embodiments provide compositions and methods related to novel recombinant protein immunogens, comprising specific portions of alpha helical domains (aHD) and proline rich regions (PRD) of pneumococcal surface protein A (PspA), which portions are linked to provide aHD-PRD constructs. The aHD and PRD proteins constituting the aHD-PRD constructs are selected to maximize cross-reactivity and provide protection against a broad spectrum of pneumococcal serotypes. Immunogenic compositions, including vaccines, comprising at least one aHD PRD construct may also include a non-linked aHD portion. Also provided are recombinant nucleic acid molecules that encode aHD-PRD constructs, vectors and recombinant host cells containing such molecules, aHD-PRD expression products, use of such nucleic acid molecules to express aHD-PRD constructs by recombinant techniques, and use of the expression products to elicit an immune or protective response against pneumococcal disease in a suitable host.

Abstract: The present invention provides a nasal vaccine for Streptococcus pneumoniae, and a production method therefor. This nasal vaccine formulation for primates includes a complex of PspA, i.e. the vaccine antigen, and a nanogel in which hydrophobic cholesterol is added, as side chains, to pullulan having amino groups. Furthermore, the present invention provides a production method for the nasal vaccine formulation for primates.

Abstract: The present invention provides a nasal vaccine for Streptococcus pneumoniae, and a production method therefor. This nasal vaccine formulation for primates includes a complex of PspA, i.e. the vaccine antigen, and a nanogel in which hydrophobic cholesterol is added, as side chains, to pullulan having amino groups. Furthermore, the present invention provides a production method for the nasal vaccine formulation for primates.

Abstract: Using a thermally assisted magnetic recording head, reference signals are recorded into a magnetic recording medium; reproduction signal intensity of the reference signals is measured in a state where the thermally assisted magnetic head has been moved in the track width direction from the track width center of the track where the reference signals are recorded; a mean signal output of each sector in the track where the reference signals are recorded is calculated from the measurement results of the reproduction signal intensity of the reference signals; and the recording characteristics of a thermally assisted magnetic head are evaluated based upon the mean signal output of the sectors.

Abstract: Using a thermally assisted magnetic recording head, reference signals are recorded into a magnetic recording medium; reproduction signal intensity of the reference signals is measured in a state where the thermally assisted magnetic head has been moved in the track width direction from the track width center of the track where the reference signals are recorded; a mean signal output of each sector in the track where the reference signals are recorded is calculated from the measurement results of the reproduction signal intensity of the reference signals; and the recording characteristics of a thermally assisted magnetic head are evaluated based upon the mean signal output of the sectors.